Bill > SF3769

This bill continues to prohibit drug manufacturers from restricting the delivery of prescription drugs obtained through the 340B program, a federal program that allows certain healthcare providers to purchase outpatient drugs at significantly reduced prices. The bill clarifies that violating these delivery restrictions is considered an unfair or deceptive trade practice, making it enforceable by the attorney general. Additionally, it removes an expiration date from the existing law, ensuring these protections remain in place indefinitely, and repeals a previous provision that would have allowed these restrictions to expire on July 1, 2027.